Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators: Discovery of 2-Chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1 H -imidazol-4-ylethynyl]pyridine (Basimglurant, RO4917523), a Promising Novel Medicine for Psychiatric Diseases
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu5) have potential for the treatment of psychiatric diseases including depression, fragile X syndrome (FXS), anxiety, obsessive-compulsive disorders, and levodopa induced dyskinesia in Parkinson's disease. Herein we report the optimization of a weakly active screening hit 1 to the potent and selective compounds chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, 2) and 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine (CTEP, 3). Compound 2 is active in a broad range of anxiety tests reaching the same efficacy but at a 10- to 100-fold lower dose compared to diazepam and is characterized by favorable DMPK properties in rat and monkey as well as an excellent preclinical safety profile and is currently in phase II clinical studies for the treatment of depression and fragile X syndrome. Analogue 3 is the first reported mGlu5 NAM with a long half-life in rodents and is therefore an ideal tool compound for chronic studies in mice and rats.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Obach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232
Pharmacological agents acting at subtypes of metabotropic glutamate receptors
Schoepp, D. D., Jane, D. E., & Monn, J. A. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00092-1 · Cited by 1,060
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Correction of Fragile X Syndrome in Mice
Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979
Evans, D. A., Katz, J. L., & West, T. R. (1998) · Tetrahedron Letters · doi:10.1016/s0040-4039(98)00502-4 · Cited by 859
Metabotropic glutamate receptors in brain function and pathology
Schoepp, D. D., & Conn, P. J. (1993) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(93)90107-u · Cited by 791 · cited 1×
“a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives with affinity for GABAA α5 binding sites for”
BackgroundGasparini, F., Lingenhöhl, K., Stoehr, N., Flor, P. J., Heinrich, M., Vranesic, I., Biollaz, M., Allgeier, H., Heckendorn, R., Urwyler, S., et al. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00082-9 · Cited by 725
Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice
Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., Jaeschke, G., Bear, M. F., & Lindemann, L. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.009 · Cited by 489
Self-citationThe role of the amygdala in fear-potentiated startle: implications for animal models of anxiety
Davis, M. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90014-w · Cited by 427
Research works printed but not linked: 4
- Rodriguez A. L., 2007, Curr. Opin. Drug Discovery Dev., 10, 715
- Lindsley C. W., 2009, Curr. Opin. Drug Discovery Dev., 12, 446
- Lindemann L., 2014, Curr. Neuropharmacol., 12, 35
- Ametamey S. M., 2006, J. Nucl. Med., 47, 698
Cited by
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Structure, function and drug discovery of GPCR signaling
Cheng, L., Xia, F., Li, Z., Shen, C., Yang, Z., Hou, H., Sun, S., Feng, Y., Yong, X., Tian, X., et al. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00156-w · Cited by 152
FragXis Study Group, Youssef, E. A., Berry-Kravis, E., Czech, C., Hagerman, R. J., Hessl, D., Wong, C. Y., Rabbia, M., Deptula, D., John, A., et al. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.177 · Cited by 133
“The early short-term clinical trials with mGluR5 NAMs, including basimglurant, assessing the effects in individuals with FXS, were supportive of further exploration in larger, well-controlled trials.”
BackgroundInfluentialSelf-citationQuiroz, J. A., Tamburri, P., Deptula, D., Banken, L., Beyer, U., Rabbia, M., Parkar, N., Fontoura, P., & Santarelli, L. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0838 · Cited by 133
Fu, T., Zheng, G., Tu, G., Yang, F., Chen, Y., Yao, X., Li, X., Xue, W., & Zhu, F. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00059 · Cited by 115
Lindemann, L., Porter, R. H., Scharf, S. H., Kuennecke, B., Bruns, A., von Kienlin, M., Harrison, A. C., Paehler, A., Funk, C., Gloge, A., et al. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222463 · Cited by 107
“1) was discovered in a medicinal chemistry effort conducted at F. Hoffmann-La Roche AG starting from the results of a small molecular weight compound library high-throughput screen based on a Ca21 mobilization assay with human mGlu5a (Jaeschke et al., 2015).”
BackgroundSelf-citationAbd‐Elrahman, K. S., Hamilton, A., Hutchinson, S. R., Liu, F., Russell, R. C., & Ferguson, S. S. G. (2017) · Science Signaling · doi:10.1126/scisignal.aan6387 · Cited by 90
Allosteric modulation of G protein-coupled receptor signaling
Shen, S., Zhao, C. S., Wu, C., Sun, S., Li, Z., Yan, W. X., & Shao, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1137604 · Cited by 87
mGlu5negative allosteric modulators: a patent review (2013 - 2016)
Emmitte, K. A. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1280466 · Cited by 79
Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions
Lacivita, E., Perrone, R., Margari, L., & Leopoldo, M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00965 · Cited by 78
Mihov, Y., & Hasler, G. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw002 · Cited by 52
Peterlik, D., Flor, P. J., & Uschold‐Schmidt, N. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150515234920 · Cited by 57
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
“Preclinical evidence indicates robust anxiolytic and antidepressant efficacy [173].”
BackgroundSengmany, K., & Gregory, K. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13281 · Cited by 49
“…et al., 2013; Pilc et al., 2013), with candidates entering clinical trials for anxiety, depression and Fragile X syndrome with varying successes and failures (Pecknold et al., 1982; Porter et al., 2005; Levenga et al., 2011; Wieronska and Pilc, 2013; Jaeschke et al., 2015; Lindemann et al., 2015).”
BackgroundSoluble tau aggregates inhibit synaptic long-term depression and amyloid β-facilitated LTD in vivo
Ondrejčák, T., Hu, N., Qi, Y., Klyubin, I. V., Corbett, G. T., Fraser, G. M., Perkinton, M. S., Walsh, D. M., Billinton, A., & Rowan, M. J. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.03.022 · Cited by 49
Fuxe, K., & Borroto-Escuela, D. O. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1074175 · Cited by 43
Yohn, S. E., Galbraith, J., Calipari, E. S., & Conn, P. J. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00601 · Cited by 36
Molecular Biomarkers in Fragile X Syndrome
Zafarullah, M., & Tassone, F. (2019) · Brain Sciences · doi:10.3390/brainsci9050096 · Cited by 38
“Similarly, extensive proof of concept study was conducted with basimglurant, a potent and selective mGluR5-negative allosteric modulator (NAM) [76,77] and mavoglurant in male and female adults with FXS.”
BackgroundIsherwood, S. N., Pekcec, A., Nicholson, J. R., Robbins, T. W., & Dalley, J. W. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3984-0 · Cited by 37
Felts, A. S., Rodriguez, A. L., Blobaum, A. L., Morrison, R. D., Bates, B. S., Gray, A. T., Rook, J. M., Tantawy, M. N., Byers, F. W., Chang, S., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00410 · Cited by 36
Synthesis of pyridine trans -tetrafluoro-λ 6 -sulfane derivatives via radical addition
Das, P., Takada, M., Tokunaga, E., Saito, N., & Shibata, N. (2017) · Organic Chemistry Frontiers · doi:10.1039/c7qo00994a · Cited by 33
Zhang, D., Qi, Y., Klyubin, I. V., Ondrejčák, T., Sarell, C. J., Cuello, A. C., Collinge, J., & Rowan, M. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.03.036 · Cited by 34
“…to determine if the rapidly reversible beneficial effects of basimglurant were a drug class effect not caused by the vehicle treatment w decided to compare the effects of corn oil with another mGlu5 receptor antagonist, CTEP (Hamilton et al., 2016; Jaeschke et al., 2015; Lindemann et al., 2011).”
BackgroundMethodResultInvestigational drugs for treating major depressive disorder
Dhir, A. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1267727 · Cited by 32
“The molecule, being developed by Roche, has 10–100 times more potency compared to diazepam (a standard antianxiety drug) in animal models of anxiety disorders [89].”
BackgroundNeuroanatomical abnormalities in fragile X syndrome during the adolescent and young adult years
Sandoval, G. M., Shim, S.-H., Hong, D. S., Garrett, A. S., Quintin, E., Marzelli, M., Patnaik, S., Lightbody, A. A., & Reiss, A. L. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.10.014 · Cited by 32
“…brain abnormalities in FXS at specific developmental stages, especially during adolescence, is essential as new disease-targeted pharmacological agents are being tested across a broad age range in individuals with FXS (Erickson et al., 2014; Jaeschke et al., 2015; Scharf et al., 2015).”
BackgroundMilanese, M., Bonifacino, T., Torazza, C., Provenzano, F., Kumar, M., Ravera, S., Zerbo, R. A., Frumento, G., Balbi, M., Nguyen, T. P. N., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15515 · Cited by 32
Galambos, J., Bielik, A., Krasavin, M., Orgován, Z., Domány, G., Nógrádi, K., Wágner, G., Balogh, G. T., Béni, Z., Kóti, J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01858 · Cited by 30
Cao, D., Zhang, P., & Wang, S. (2024) · Neuron · doi:10.1016/j.neuron.2024.01.004 · Cited by 33
Biased agonism and allosteric modulation of metabotropic glutamate receptor 5
Trinh, P. N. H., May, L. T., Leach, K., & Gregory, K. J. (2018) · Clinical Science · doi:10.1042/cs20180374 · Cited by 29
Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date
Fung, L. K., & Hardan, A. Y. (2015) · CNS Drugs · doi:10.1007/s40263-015-0252-0 · Cited by 29
Lebl, R., Murray, T., Adamo, A., Cantillo, D., & Kappe, C. O. (2019) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.9b05954 · Cited by 28
Beyond serotonin: newer antidepressants in the future
Rakesh, G., Pae, C., & Masand, P. S. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1341310 · Cited by 28
“Animal studies showed significant antidepressant and anxiolytic properties [105,106].”
BackgroundMcGarry, K. A., Duenas, A. A., & Clark, T. B. (2015) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5b01074 · Cited by 20
Arsova, A., Møller, T. C., Vedel, L., Hansen, J. L., Foster, S. R., Gregory, K. J., & Bräuner‐Osborne, H. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.119032 · Cited by 20
“Basimglurant, a very potent mGlu5 NAM with long half-life in rats, has reached phase II clinical trials for the treatment of fragile X syndrome and as an adjunctive therapy in major depressive disorder (Jaeschke et al., 2015; Lindemann et al., 2015).”
BackgroundBlocking metabotropic glutamate receptor subtype 5 relieves maladaptive chronic stress consequences
Peterlik, D., Stangl, C., Bauer, A., Bludau, A., Keller, J., Grabski, D., Killian, T., Schmidt, D., Zajicek, F., Jaeschke, G., et al. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.08.007 · Cited by 20
Self-citationLenz, B. F., Brink, A., Siam, M., Paepe, A. D., Bassett, S., Eichinger‐Chapelon, A., Maliver, P., Neff, R., Niederhauser, U., Steinhuber, B., et al. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx044 · Cited by 17
Self-citationHarde, E., Hierl, M., Weber, M., Waiz, D., Wyler, R., Wach, J.-Y., Haab, R., Gundlfinger, A., He, W., Schnider, P., et al. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2023.11.004 · Cited by 14
Du, Y., Gao, F., Sun, H., Wu, C., Zhu, G., & Zhu, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115855 · Cited by 14
Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients
Morissette, M., Morin, N., Grégoire, L., Rajput, A. H., Rajput, A. H., & Paolo, T. D. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.03.023 · Cited by 14
Kos, J. A., Langiu, M., Hellyer, S. D., & Gregory, K. J. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00213 · Cited by 16
Graziani, D., Caligari, S., Callegari, E., Toma, C. D., Longhi, M., Frigerio, F., Dilernia, R., Menegon, S., Pinzi, L., Pirona, L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01226 · Cited by 16
Hasyeoui, M., Chapple, P. M., Lassagne, F., Roisnel, T., Cordier≈, M., Samarat, A., Sarazin, Y., & Mongin, F. (2023) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202300555 · Cited by 12
Torazza, C., Provenzano, F., Gallia, E., Cerminara, M., Balbi, M., Bonifacino, T., Tessitore, S., Ravera, S., Usai, C., Musante, I., et al. (2023) · Cells · doi:10.3390/cells12151952 · Cited by 13
Felts, A. S., Bollinger, K. A., Brassard, C. J., Rodriguez, A. L., Morrison, R. D., Daniels, J. S., Blobaum, A. L., Niswender, C. M., Jones, C. K., Conn, P. J., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.11.017 · Cited by 11
Streffer, J. R., Treyer, V., Buck, A., Ametamey, S. M., Blagoev, M., Maguire, R. P., Gautier, A., Auberson, Y. P., Schmidt, M. E., Vranesic, I.-T., et al. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.117785 · Cited by 12
Jmaeff, S., Sidorova, Y. A., Lippiatt, H., Barcelona, P. F., Nedev, H. N., Saragovi, L. M., Hancock, M. A., Saarma, M., & Saragovi, H. U. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.118950 · Cited by 10
Belhocine, A., Veglianese, P., Hounsou, C., Dupuis, E., Acher, F., Durroux, T., Goudet, C., & Pin, J. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.07.032 · Cited by 10
Biased signaling in drug discovery and precision medicine
Ji, R., & Tao, Y. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108804 · Cited by 9
Jiang, L., Li, Y., Qiao, L., Chen, X., He, Y., Zhang, Y., & Li, G. (2015) · Canadian Journal of Chemistry · doi:10.1139/cjc-2015-0197 · Cited by 8
Fowler, S. M., Guerini, E., Qiu, N., Cleary, Y., Parrott, N. J., Greig, G., & Mallalieu, N. L. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.237214 · Cited by 9
“…also elicited dose-dependent anxiolytic-like effects in the stress-induced hyperthermia model in mice and showed activity in antidepressant-like rat models, including the forced swim test, as well as the chronic mild stress and anhedonia model (Jaeschke et al., 2015; Lindemann et al., 2015).”
BackgroundRossi, R., & Ciofalo, M. (2019) · Current Organic Chemistry · doi:10.2174/1385272823666191014154129 · Cited by 9
Cosson, V., Schaedeli‐Stark, F., Arab‐Alameddine, M., Chavanne, C., Guerini, E., Derks, M., & Mallalieu, N. L. (2018) · Clinical and Translational Science · doi:10.1111/cts.12566 · Cited by 7
7TM X-ray structures for class C GPCRs as new drug-discovery tools. 1. mGluR5
Topiol, S., & Sabio, M. L. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.11.087 · Cited by 8
Masilamoni, G. J., & Smith, Y. (2019) · Brain Structure and Function · doi:10.1007/s00429-019-01937-2 · Cited by 5
Crocker, K. E., Henderson, S. H., Capstick, R. A., Whomble, D. L., Bender, A. M., Felts, A. S., Han, C., Engers, J. L., Billard, N. B., Maurer, M. A., et al. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00119 · Cited by 4
Pharmacological Treatments for Fragile X Syndrome Based on Synaptic Dysfunction
Telias, M. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191102165206 · Cited by 4
Modulating Neuroplasticity: Lessons Learned from Antidepressants and Emerging Novel Therapeutics
Yates, C. G., Kruse, J. L., Price, J. B., Robertson, A. A. B., & Tye, S. J. (2021) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-021-00249-9 · Cited by 4
Childress, E. S., Capstick, R. A., Crocker, K. E., Ledyard, M. L., Bender, A. M., Maurer, M. A., Billard, N. B., Cho, H. P., Rodriguez, A. L., Niswender, C. M., et al. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00481 · Cited by 3
David, T. K., Prashanth, N. K., Rajendraswami, M., Pallalu, D., Castelhano, A. L., Kates, M. J., Blobaum, A. L., Jones, C. K., Emmitte, K. A., Conn, P. J., et al. (2017) · Tetrahedron Letters · doi:10.1016/j.tetlet.2017.07.100 · Cited by 3
Jismy, B., Qami, A. E., Jacquemin, J., Guillot, R., Tikad, A., & Abarbri, M. (2021) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202100632 · Cited by 2
Selvam, C., Thilagavathi, R., Narasimhan, B., Kumar, P., Jordan, B. C., & Ranganna, K. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.01.051 · Cited by 2
Henderson, S. H., Ringuette, A. E., Whomble, D. L., Capstick, R. A., Richardson, A. E., Maurer, M. A., Billard, N. B., Lei, X., Wilkinson, J. C., Kethanapalli, S. H., et al. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00896 · Cited by 1
Yoshikawa, K., Ohyama, T., Takahashi, E., Numajiri, Y., Konno, M., Moriyama, M., Takemi, N., Kunita, K., Nishimura, K., & Hayashi, R. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.06.008 · Cited by 1
Peterlik, D. (2017) · University of Regensburg Publication Server (University of Regensburg)
An Introduction to the CNS Section of Volume 7: Recent Approvals and Advances in CNS Drug Discovery
Hall, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803200-8.02004-6
Singh, P., Patra, J., Saeedan, A. S., Aldossary, S. A., & Ansari, M. N. (2026) · Research in Pharmaceutical Sciences · doi:10.4103/rps.rps_61_25
“Amongst these, NAMs such as mavoglurant (18), dipraglurant (19), basimglurant (20), 2-[2-(3-methoxyphenyl)ethynyl]-6-methyl-pyridine (M-MPEP) (21), VU0424238 (22), carbamoyloximes (23), 4-amino-3-arylsulfoquinolines (24), and HTL14242 (25) have been considered leading therapeutic candidates.”
BindingDB (2019) · UC San Diego · doi:10.7270/q2377c5d
BindingDB (2019) · UC San Diego · doi:10.7270/q2rv0r05
BindingDB (2017) · UC San Diego · doi:10.7270/q21c1zq3
Metadata
- Authors
- Jaeschke, G., Kolczewski, S., Spooren, W., Vieira, E., Bitter-Stoll, N., Boissin, P., Borroni, E., Büttelmann, B., Ceccarelli, S., Clemann, N., David, B., Funk, C., Guba, W., Harrison, A., Hartung, T., Honer, M., Huwyler, J., Kuratli, M., Niederhauser, U., Pähler, A., Peters, J.-U., Petersen, A., Prinssen, E., Ricci, A., Rueher, D., Rueher, M., Schneider, M., Spurr, P., Stoll, T., Tännler, D., Wichmann, J., Porter, R. H., Wettstein, J. G., & Lindemann, L.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- University of Basel (CH)
- Corresponding author
- Jaeschke, Georg
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-02-02
- Volume
- 58
- Issue
- 3
- Pages
- 1358-1371
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2011170609
- Cited by
- 66
- References
- 45
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 3 · 2023: 8 · 2021: 4 · 2020: 2 · 2019: 8 · 2018: 6 · 2017: 12 · 2016: 7 · 2015: 10
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- metabotropic glutamate receptor 5, negative allosteric modulators, CTEP, antidepressant drug discovery, fragile X syndrome, anxiety, depression, levodopa-induced dyskinesia, drug metabolism and pharmacokinetics, preclinical safety, structure-activity optimization
- MeSH terms
- Allosteric Regulation, Animals, Depression, Dose-Response Relationship, Drug, Fragile X Syndrome, Humans, Imidazoles, Macaca mulatta, Male, Mice, Inbred Strains, Pyridines, Structure-Activity Relationship, Molecular Structure, Rats, Sprague-Dawley, Rats, Wistar, Mice, Rats, Drug Discovery, Receptor, Metabotropic Glutamate 5
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.